IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones . : Fase III Actualizada A Randomized, Multicenter .Yondelis Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With TRS .

11 enero 2011

Fase III Actualizada A Randomized, Multicenter .Yondelis Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With TRS .

A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS) .

This study is currently recruiting participants.

Verified by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., January 2011 .

First Received: November 20, 2008 Last Updated: January 7, 2011 .

...